SCHEMBL29321909

SCHEMBL29321909

COc1ccc(CN(Cc2ccc(OC)cc2)c2nccnc2[C@@H](C)NCCO)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.41
▸ MAPT P10636 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ HTT P42858 2/20 0.39
▸ TSHR P16473 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ DRD1 P21728 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27089390 0.84 LMNA (0.44) LMNAMAPTSMN1; SMN2HTTTSHR
SCHEMBL30897996 0.84 LMNA (0.44) LMNAMAPTSMN1; SMN2HTTTSHR
SCHEMBL27089386 0.84 LMNA (0.44) LMNAMAPTSMN1; SMN2HTTTSHR
SCHEMBL32669363 0.79 LMNA (0.47) LMNAMAPTTSHRALDH1A1CYP1A2
SCHEMBL27088677 0.78 CCNE2 (0.51) RAB9ACCNE2CCNE1CDK2PRUNE1
SCHEMBL27088683 0.78 CCNE2 (0.51) RAB9ACCNE2CCNE1CDK2PRUNE1
SCHEMBL27089334 0.78 CCNE2 (0.51) RAB9ACCNE2CCNE1CDK2PRUNE1
SCHEMBL29322620 0.77 APLNR (0.40) LMNAMAPTSMN1; SMN2HTTALDH1A1
SCHEMBL27088502 0.77 APLNR (0.40) LMNAMAPTSMN1; SMN2HTTALDH1A1
SCHEMBL27089259 0.74 CASR (0.40) LMNAMAPTSMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228512-A1 ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF GENENTECH, INC. (US) 2024-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228512-A1 ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF AZI2, HDAC5, HDAC4 LMNA 4375/4885MAPT 3890/4885SMN1; SMN2 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback